Free Trial
NASDAQ:AKRO

Akero Therapeutics (AKRO) Stock Price, News & Analysis

Akero Therapeutics logo
$51.32 +0.95 (+1.88%)
As of 12:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Akero Therapeutics Stock (NASDAQ:AKRO)

Key Stats

Today's Range
$50.97
$53.60
50-Day Range
$37.88
$56.28
52-Week Range
$21.34
$58.40
Volume
624,641 shs
Average Volume
1.05 million shs
Market Capitalization
$4.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$82.50
Consensus Rating
Buy

Company Overview

Akero Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

AKRO MarketRank™: 

Akero Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 293rd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Akero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Akero Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Akero Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Akero Therapeutics are expected to decrease in the coming year, from ($3.99) to ($4.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Akero Therapeutics is -26.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Akero Therapeutics is -26.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Akero Therapeutics has a P/B Ratio of 4.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Akero Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.46% of the float of Akero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akero Therapeutics has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Akero Therapeutics has recently increased by 12.16%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Akero Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Akero Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.46% of the float of Akero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akero Therapeutics has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Akero Therapeutics has recently increased by 12.16%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Akero Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Akero Therapeutics this week, compared to 7 articles on an average week.
  • Search Interest

    Only 3 people have searched for AKRO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,817,160.00 in company stock.

  • Percentage Held by Insiders

    Only 7.07% of the stock of Akero Therapeutics is held by insiders.

  • Read more about Akero Therapeutics' insider trading history.
Receive AKRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKRO Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

AKRO Stock Analysis - Frequently Asked Questions

Akero Therapeutics' stock was trading at $27.82 at the beginning of the year. Since then, AKRO stock has increased by 84.1% and is now trading at $51.2270.

Akero Therapeutics, Inc. (NASDAQ:AKRO) released its quarterly earnings results on Monday, May, 12th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of ($1.01) by $1.91.

Akero Therapeutics (AKRO) raised $75 million in an IPO on Thursday, June 20th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager.

Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akero Therapeutics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
5/12/2025
Today
7/09/2025
Next Earnings (Estimated)
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AKRO
CIK
1744659
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$109.00
Low Price Target
$64.00
Potential Upside/Downside
+63.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$252.06 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$10.75 per share
Price / Book
4.69

Miscellaneous

Free Float
74,082,000
Market Cap
$4.02 billion
Optionable
Optionable
Beta
-0.15
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:AKRO) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners